Results of analysis of the sarcoidosis registry of the Republic of Tatarstan

Sarcoidosis is a systemic epithelioid cell granulomatosis of unknown origin. The specialized commission on pulmonology of the Russian Ministry of Health recommended creating a register for sarcoidosis in the beginning of 2023. The aim of the study was to assess the main characteristics of newly identified patients with sarcoidosis according to the register created in the Republic of Tatarstan as a pilot project. Methods. Information on the newly identified patients was collected from 1996 to 2023. Statistical processing of 3,037 cases of sarcoidosis was carried out using the SPSS-18 program (IBM, USA). The p-value < 0.05 was considered statistically significant. Results. From 1 967 to 2 023, 3,037 cases of sarcoidosis were entered in the registry, including 2 094 women (68.9%) and 943 men (31.1%). The median age was 45 (34; 55) years, with 36 – 55 years of age being associated with the highest incidence. The men were much younger than the women. There was an increase in detection in 2017 (161 patients) with a subsequent decrease during the COVID-19 pandemic and recovery in subsequent years. 18 (0.6%) patients had X-ray stage 0, 1,162 (38.3 %) – stage I, 1,527 (50.3%) – stage II, 302 (9.0%) – stage III, and 28 (0.9%) – stage IV. Löfgren’s syndrome was present in 387 (12.7%) patients, and extrapulmonary manifestations were found in 576 patients (19.0%). Identification rate in different regions of Tatarstan correlated with the size of the population. Overall, 44.7% patients had biopsy results, along with 47.3% before COVID-19 pandemic and 72.5% after the pandemic. After identification, a combination of pentoxifylline with vitamin E was prescribed in 32.9%, and vitamin E alone in 30.3%. Systemic corticosteroids were prescribed in 17.5%, and active monitoring without treatment was recommended in 15.8% cases. Postponing of immunosuppression was compliant with the clinical guidelines in Tatarstan. Conclusion. Analysis of data from the sarcoidosis register of the Republic of Tatarstan revealed an increase in detection before the COVID-19 pandemic, a decrease during the pandemic, and a resumption of growth together with an increase in biopsies afterwards. Management of patients after the diagnosis was characterized by the predominant active surveillance and immunosuppression strictly according to the therapeutic indications.

1. Vizel I.Yu., Vizel A.A. [Characteristics of the register of patients with sarcoidosis in the Republic of Tatarstan]. Vestnik sovremennoy klinicheskoy meditsiny. 2015; 8 (5): 18–26. Available at: http://www.vskmjournal.org/ru/vypuski-zhurnala/19-2015-ru/18-tom-8-vypusk-5-2015.html#a18 (in Russian).

2. Vizel A.A., Shakirova G.R., Vizel I.Yu. et al. [Database of patients with sarcoidosis of the Republic of Tatarstan: a retrospective analysis for 50 years]. Al'manakh klinicheskoy meditsiny. 2020; 48 (5): 291–298. DOI: 10.18786/2072-0505-2020-48-055 (in Russian).

3. Gabriel E.E., Arkema E.V., Sachs M.C. Direct modeling of relative and absolute risks in register data: Mortality risk in sarcoidosis. Ann. Epidemiol. 2022; 66: 1–4. DOI: 10.1016/j.annepidem.2021.11.003.

4. Nashatyreva M.S., Trofimenko I.N., Chernyak B.A. [Clinical features of interstitial lung diseases according to data from the Irkutsk Register]. Pul'monologiya. 2017; 27 (6): 740–747. DOI: 10.18093/0869-0189-2017-27-6-740-747 (in Russian).

5. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Sarcoidosis: federal clinical guidelines for diagnosis and treatment]. Pul’monologiya. 2022; 32 (6): 806–833. DOI: 10.18093/0869-0189-2022-32-6-806-833 (in Russian).

6. Vizel A.A., Vizel I.Yu., Shakirova GR, Vizel LA. [Characteristics of patients with sarcoidosis who consulted a pulmonologist during the COVID-19 pandemic]. Meditsinskiy sovet. 2023; 17 (20): 26–33. DOI: 10.21518/ms2023-289 (in Russian).

7. Desbois A.C., Marques C., Lefèvre L. et al. Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. Clin. Exp. Rheumatol. 2022; 40 (1): 195–196. DOI: 10.55563/clinexprheumatol/b7zd6b.

8. Khan M.A., Ibad H.A., Hamid Hussain S.M. et al. Sarcoidosis: An experience from a tertiary care center in Karachi Pakistan. J. Pak. Med. Assoc. 2022; 72 (4): 785–789. DOI: 10.47391/JPMA.0411.

9. Thillai M., Chang W., Chaudhuri N. et al. Sarcoidosis in the UK: insights from British Thoracic Society registry data. BMJ Open Respir. Res. 2019; 6 (1): e000357. DOI: 10.1136/bmjresp-2018-000357.

10. Masumoto N., Watanabe K., Horita N. et al. Elderly sarcoidosis in Japan. J. Int. Med. Res. 2022; 50 (12): 3000605221142705. DOI: 10.1177/03000605221142705.

11. Speranskaya A.A., Baranova O.P., Kudryashova T.G., Yartseva E.E. [Clinical and radiological features of respiratory sarcoidosis in young people]. Vizualizatsiya v meditsine. 2022; 4 (1): 16–25. Available at: https://ojs3.gpmu.org/index.php/visual-med/article/view/4091 (in Russian).

12. Konak H.E., Güven S.C., Atalar E. et al. A single-center rheumatology experience of sarcoidosis: observations from 70 patients. Sarcoidosis Vasc. Diffuse Lung Dis. 2023; 40 (3): e2023033. DOI: 10.36141/svdld.v40i3.14063.

13. Park J.E., Kim Y.S., Kang M.J. et al. Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003-2015: a nationwide population-based study. Respir. Med. 2018; 144S: S28–34. DOI: 10.1016/j.rmed.2018.03.028.

14. Seedahmed M.I., Baugh A.D., Albirair M.T. et al. Epidemiology of sarcoidosis in U.S. veterans from 2003 to 2019. Ann. Am. Thorac. Soc. 2023; 20 (6): 797–806. DOI: 10.1513/AnnalsATS.202206-515OC.

15. Smirnova M.S., Berezhonova M.S. [Standardization of medical care for patients with sarcoidosis]. Problemy standartizatsii v zdravookhranenii. 2018; (1-2): 14–24. DOI: 10.26347/1607-2502201801-02014-019 (in Russian).

16. Gade Sikjær M., Hilberg O., Ibsen R. et al. Direct and indirect economic and health consequences related to sarcoidosis in Denmark: a national register-based study. Respir. Med. 2019; 152: 7–13. DOI: 10.1016/j.rmed.2019.04.004.

17. Morimoto T., Azuma A., Abe S. et al. Epidemiology of sarcoidosis in Japan. Eur. Respir. J. 2008; 31 (2): 372–379. DOI: 10.1183/09031936.00075307.

18. Haraldsdóttir S.Ó., Jonasson J.G., Jorundsdottir K.B. et al. Sarcoidosis in Iceland: a nationwide study of epidemiology, clinical picture and environmental exposure. ERJ Open Res. 2021; 7 (4): 00550-2021. DOI: 10.1183/23120541.00550-2021.